Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo

K. C. Zachary; G. J. Hanna; R. T. D'Aquila

doi:10.1086/324510

Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo

K. C. Zachary^*, G. J. Hanna, R. T. D'Aquila

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

The human immunodeficiency virus type 1 protease mutation N88S, which is occasionally selected by treatment with nelfinavir or indinavir, confers hypersusceptibility to amprenavir in vitro. The clinical relevance of this observation is unclear. We report a case of N88S developing after virologic failure of both indinavir- and nelfinavir-containing regimens that was managed successfully with a regimen that contained amprenavir.

Original language	English (US)
Pages (from-to)	2075-2077
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	33
Issue number	12
DOIs	https://doi.org/10.1086/324510
State	Published - Dec 15 2001

Funding

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/324510

Cite this

@article{e0fec41dbfaf4ab2923bcf08b1c621e7,

title = "Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo",

abstract = "The human immunodeficiency virus type 1 protease mutation N88S, which is occasionally selected by treatment with nelfinavir or indinavir, confers hypersusceptibility to amprenavir in vitro. The clinical relevance of this observation is unclear. We report a case of N88S developing after virologic failure of both indinavir- and nelfinavir-containing regimens that was managed successfully with a regimen that contained amprenavir.",

author = "Zachary, {K. C.} and Hanna, {G. J.} and D'Aquila, {R. T.}",

year = "2001",

month = dec,

day = "15",

doi = "10.1086/324510",

language = "English (US)",

volume = "33",

pages = "2075--2077",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo

AU - Zachary, K. C.

AU - Hanna, G. J.

AU - D'Aquila, R. T.

PY - 2001/12/15

Y1 - 2001/12/15

N2 - The human immunodeficiency virus type 1 protease mutation N88S, which is occasionally selected by treatment with nelfinavir or indinavir, confers hypersusceptibility to amprenavir in vitro. The clinical relevance of this observation is unclear. We report a case of N88S developing after virologic failure of both indinavir- and nelfinavir-containing regimens that was managed successfully with a regimen that contained amprenavir.

AB - The human immunodeficiency virus type 1 protease mutation N88S, which is occasionally selected by treatment with nelfinavir or indinavir, confers hypersusceptibility to amprenavir in vitro. The clinical relevance of this observation is unclear. We report a case of N88S developing after virologic failure of both indinavir- and nelfinavir-containing regimens that was managed successfully with a regimen that contained amprenavir.

UR - http://www.scopus.com/inward/record.url?scp=0035893128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035893128&partnerID=8YFLogxK

U2 - 10.1086/324510

DO - 10.1086/324510

M3 - Article

C2 - 11700580

AN - SCOPUS:0035893128

SN - 1058-4838

VL - 33

SP - 2075

EP - 2077

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 12

ER -

Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this